Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

61 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-25

Study Completion Date

2021-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise capacity will be evaluated in patients with pulmonary arterial hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aerobic Exercise Training in Pulmonary Arterial Hypertension

NCT02371733

Pulmonary Arterial Hypertension

COMPLETED NA

Inspiratory Muscle Training in Pulmonary Hypertension

NCT03385733

Pulmonary Hypertension

COMPLETED NA

Comparison of Respiratory Muscle, Pain, Functional Performance and Cognitive Status in Obstructive Lung Diseases

NCT04048408

Pain, Chronic Obstructive Pulmonary Disease Cognitive Impairment +1 more

COMPLETED

Maximal Exercise Capacity, Physical Activity and Respiratory Muscle Strength in Peripheral Artery Disease

NCT03458754

Peripheral Arterial Disease

COMPLETED

The Relationship Between Upper Extremity Exercise Capacity, Respiratory and Peripheral Muscle Strength in Chronic Low Back Pain

NCT06806514

Chronic Low Back Pain

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although main symptoms of pulmonary arterial hypertension (PAH) include shortness of breath and exercise intolerance, patients may also experience symptoms related to musculoskeletal system such as muscle fatigue or pain. Due to insufficient cardiac output and chronic arterial hypoxemia, oxygen cannot be delivered to skeletal muscles sufficiently, especially during exertion. In addition, inflammation, which is thought to play an important role in pulmonary vascular remodeling and disease pathophysiology in these patients, affects skeletal muscles as well. Increased sympathetic tone in PAH restricts the perfusion of skeletal muscle by increasing peripheral vascular resistance. With the addition of physical inactivity to all these factors, skeletal muscle metabolism is further impaired. Furthermore, drugs used for the treatment of PAH may induce musculoskeletal pain as a side effect. Musculoskeletal pain is one of the most important factors impairing individual's quality of life, regardless of whether there is an underlying disease. Our aim in this study is to evaluate pain prevalence in the musculoskeletal system over 9 body regions, to compare the pain prevalence of patients using different types of PAH drugs and to examine impact of musculoskeletal pain on quality of life and functional capacity in patients with PAH.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary arterial hypertension

Adult patients with pulmonary arterial hypertension

Evaluation of musculoskeletal pain prevalence

Intervention Type OTHER

Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.

Evaluation of quality of life

Intervention Type OTHER

Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.

Evaluation of functional exercise capacity

Intervention Type OTHER

Functional exercise capacity will be evaluated using 6-min walk test.

Evaluation of physical activity level

Intervention Type OTHER

Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evaluation of musculoskeletal pain prevalence

Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.

Intervention Type OTHER

Evaluation of quality of life

Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.

Intervention Type OTHER

Evaluation of functional exercise capacity

Functional exercise capacity will be evaluated using 6-min walk test.

Intervention Type OTHER

Evaluation of physical activity level

Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of pulmonary arterial hypertension

Exclusion Criteria

* Diagnosis of heart failure or any chronic respiratory disease
* Recent coronary bypass surgery
* Recent acute myocardial infarction
* Having a pacemaker
* Having any orthopedic or neurologic diseases which may impede walking or exercising

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No